Corvus Pharmaceuticals Inc. Common Stock (CRVS)
Stock · NASDAQ · Health Care
$9.52as of 10/16/2026
Price chart
Active signals
CRVS Signal Track Record
How signals performed across all stocks →What CRVS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +6.1% | 60% | September 3, 2026 |
| Bollinger Band Breakout | 25 | +3.8% | 52% | June 26, 2026 |
| Bollinger Band Breakdown | 21 | +7.8% | 62% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +12.8% | 56% | September 8, 2026 |
| Any 20-session window (baseline) | +2.4% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinic…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 37
- Website
- www.corvuspharma.com/
Fundamentals
- 1-day range
- $9.43$9.81
- Market cap
- $1.17B
- P/E (trailing)
- —
- P/E (forward)
- -8.92
- EPS (trailing)
- $-0.62
- Dividend yield
- —
- Beta
- 1.58
- Avg. volume
- 976.8K
Forecasts
7 analyst ratings
Corvus Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CRVSCorvus Pharmaceuticals Inc. Common Stock$9.52▼ 3.35%Market cap $1.17BP/E —$6.39$26.95
- WVEWave Life Sciences Ltd. Ordinary Shares$3.13▼ 1.88%Market cap $1.19BP/E —$3.56$21.73
- SVRASavara Inc. Common Stock$4.45▼ 6.12%Market cap $1.19BP/E —$3.38$7.01
- ARDXArdelyx Inc. Common Stock$3.09▼ 5.50%Market cap $1.20BP/E —$3.06$8.4
- ANROAlto Neuroscience Inc. Common Stock$21.94▼ 3.01%Market cap $1.11BP/E —$5.23$37.48
- IVAInventiva S.A. American Depository Shares$2.94▼ 5.47%Market cap $1.10BP/E —$2.57$6.2
- JBIOJade Biosciences Inc. Common Stock$13.47▼ 2.11%Market cap $1.10BP/E —$8.36$28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CRVS Corvus Pharmaceuticals Inc. Common Stock | $1.17B | — | $9.52 | ▼ 3.35% | $6.39$26.95 |
| WVE Wave Life Sciences Ltd. Ordinary Shares | $1.19B | — | $3.13 | ▼ 1.88% | $3.56$21.73 |
| SVRA Savara Inc. Common Stock | $1.19B | — | $4.45 | ▼ 6.12% | $3.38$7.01 |
| ARDX Ardelyx Inc. Common Stock | $1.20B | — | $3.09 | ▼ 5.50% | $3.06$8.4 |
| ANRO Alto Neuroscience Inc. Common Stock | $1.11B | — | $21.94 | ▼ 3.01% | $5.23$37.48 |
| IVA Inventiva S.A. American Depository Shares | $1.10B | — | $2.94 | ▼ 5.47% | $2.57$6.2 |
| JBIO Jade Biosciences Inc. Common Stock | $1.10B | — | $13.47 | ▼ 2.11% | $8.36$28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis SuppurativaYahoo · 9/30/2026
- Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis SuppurativaBenzinga · 9/30/2026
- Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?Yahoo · 9/25/2026
Insider Activity
Insider Actions →- David Scott Moore · June 11, 2026 · Grant15.0K
- David Scott Moore · June 11, 2026 · Buy21.7K @ $11.53
- van den Broek Richard · June 11, 2026 · Grant15.0K
- Linda Grais · June 11, 2026 · Grant15.0K
- Peter A. Thompson · June 11, 2026 · Grant15.0K
- Ian T. Clark · June 11, 2026 · Grant15.0K
- Richard A. Miller, MD · May 18, 2026 · Buy1.9K @ $12.01
- Richard A. Miller, MD · May 18, 2026 · Buy5.0K @ $12.05
- Chan Andrew C. · April 23, 2026 · Grant30.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 70.33M
- Total value held
- $983.35M
- Institutional holders
- 161
- Unknown7.17M
- Unknown6.16M
- Unknown3.57M
- Unknown3.28M
- Unknown3.23M
- Unknown2.92M
- Unknown2.81M
- Unknown2.50M
- Unknown2.49M
- Unknown2.32M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Corvus Pharma Q2 2026 Earnings Call Transcript Released
Corvus Pharmaceuticals released the transcript of its Q2 2026 earnings call. The document offers details on the company’s recent financial results and guidance for the upcoming period. Investors can review the call to better understand the company’s performance and strategic priorities.
Corvus Pharma Q2 2026 Earnings Call Transcript Released. Corvus Pharmaceuticals released the transcript of its Q2 2026 earnings call. The document offers details on the company’s recent financial results and guidance for the upcoming period. Investors can review the call to better understand the company’s performance and strategic priorities.